Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery - Wikidata - wikimedia - TriplyDB

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

http://www.wikidata.org/entity/Q36583022

about

Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection.T cell exclusion, immune privilege, and the tumor microenvironment Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.Microenvironmental regulation of therapeutic response in cancer Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.Intraoperative near-infrared imaging can identify pulmonary nodules.Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model.Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.Intraoperative near-infrared fluorescence imaging and spectroscopy identifies residual tumor cells in wounds.Regulatory considerations for clinical development of cancer vaccines Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.Optimization of the enhanced permeability and retention effect for near-infrared imaging of solid tumors with indocyanine green Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.Comparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging.Quantification of tumor fluorescence during intraoperative optical cancer imaging.Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.Intraoperative imaging identifies thymoma margins following neoadjuvant chemotherapy.Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.Elevated MTSS1 expression associated with metastasis and poor prognosis of residual hepatitis B-related hepatocellular carcinoma.Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression Immunotherapies in sarcoma: Updates and future perspectives The importance of the tumor microenvironment in the therapeutic management of cancer.Combination cancer immunotherapies tailored to the tumour microenvironment.Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia.Clinical implications of positive margins following non-small cell lung cancer surgery.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Identification of breast cancer margins using intraoperative near-infrared imaging.TNF Counterbalances the Emergence of M2 Tumor Macrophages Immune checkpoint inhibitors renal side effects and management.Intraoperative Near-Infrared Optical Imaging Can Localize Gadolinium-Enhancing Gliomas During Surgery.Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.Preventing inflammation inhibits biopsy-mediated changes in tumor cell behavior.Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.Glioma resection and tumor recurrence: back to Semmelweis.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.

P2860

Q27308955-A1DED6C2-F718-453A-BF98-FAB123EEF1C5 Q28259872-66F830BD-67DD-4838-A886-175BA3BE3D58 Q30415659-F14B9FA6-D43C-4954-97EB-BF97BF0EBDC0 Q33654609-EFC64A70-10B5-491D-98F5-97ACDCE750A2 Q33816141-CFDB57C7-2EBB-40ED-BC28-DD8DEF319FC4 Q34289985-17B73DF1-19CF-4234-80BF-B491D4037BE3 Q34402141-8EBD6CB8-69F3-4756-94A9-24C6A68B0DE4 Q34458331-24784A55-E5FD-479A-AF0C-4DB6D01ECB9D Q34558889-91AB794E-1C45-4F76-962D-623791AC3D6C Q34984596-D454E52C-7199-4002-AF8E-59BBCFBC0E6C Q35060384-0A6B8A62-0F51-421A-8311-02B5F67E0C0B Q35655447-2F5B313A-E543-4C89-A023-5D300541B4FB Q35793791-354D2779-90CC-4597-A327-9C44CD287468 Q35836887-3135B42A-B02A-4095-ADA1-EC2F3E8EBB57 Q35886454-6FC18000-0E26-4DAD-BD33-70F0FD85E22A Q35886752-5962C77E-B3E7-4AE7-8077-88B7665E7F24 Q35929728-40860FEC-C6C5-44FF-B3FB-9E394C2DF82F Q36004154-D14B677A-118F-4D37-8A18-8834889F19DE Q36146218-F2C6749E-9574-4C69-A7BE-11A876369894 Q36275679-336F5759-738A-4123-8899-74382C81F584 Q36298492-FCCDBA81-760D-4D74-92A7-6B189A1479F0 Q36772031-2C855685-8F1C-428B-BD0F-FA339365D4C5 Q36821179-374210CD-14A0-430D-80DF-901AA53823AB Q36937807-FAA38E50-9402-4788-B2C9-86C3E8CB62D6 Q37457716-84BCFA78-7ADF-4DCA-B5EE-D35DA2794322 Q37743055-0FD92A7A-1ABE-4BE6-A187-33177EF65666 Q38534294-9AE09002-40F8-4FDD-B13A-784F4AFCA21F Q38645178-152B645F-6B93-4B22-BA80-454A93854184 Q38682559-6936E73A-A1E8-458B-8BAF-CA06A3D04207 Q38683644-C6704301-B33E-4350-AFAF-219ACA936248 Q38769021-E451C968-C350-427E-8E24-58216602D0CC Q38796801-2FE06437-0E59-4544-AB24-AE254B32ACB5 Q38835677-6603D65C-314C-4B49-8F3C-4FDBB831D6A7 Q39045614-5C291F42-EFF3-44CA-932C-67971F246CB6 Q39291410-EB056CFC-4270-4172-88B3-AA4ED36427C6 Q40153561-406F6C90-A996-4B8B-A7F1-2CFAD8825669 Q41311867-56037D03-1C37-4365-8717-A1C0A6962FCB Q47104348-5A845A8C-AB78-4E09-94DA-073CF7272830 Q47148935-E8758CE0-106D-43F5-B403-8D265AFD02CD Q47701712-8E305013-54BA-43AF-B883-5EA3188924FF

P2860

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

http://www.wikidata.org/entity/Q36583022

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Changes in the local tumor mic ...... lure of vaccines after surgery

@ast

Changes in the local tumor mic ...... lure of vaccines after surgery

@en

type

label

Changes in the local tumor mic ...... lure of vaccines after surgery

@ast

Changes in the local tumor mic ...... lure of vaccines after surgery

@en

prefLabel

Changes in the local tumor mic ...... lure of vaccines after surgery

@ast

Changes in the local tumor mic ...... lure of vaccines after surgery

@en

P1433

Q36583022-14F9B641-EFBE-4E9E-986E-46E698CA3742

P1476

Q36583022-A09DA039-3425-460E-A91C-19862296D5BE

P2093

Q36583022-07394D1F-9E7D-4BCA-8104-4CA81C428025

Q36583022-2571DC00-6E25-4995-AF97-2BE97C813E41

Q36583022-29FCBC15-42A3-467C-B365-B4173F481530

Q36583022-2D655928-8291-472E-9A3F-D2D87D586325

Q36583022-4610F267-D135-4BAE-874F-B48938D3261E

Q36583022-46B8B55C-533E-452B-94A9-5C04E3053AB5

Q36583022-4BBFA707-5C5D-4DEC-85A2-F005DB30B4D6

Q36583022-76E0FB04-1D5B-49AE-8174-5478149DB1A1

Q36583022-B298CB4D-A104-4C53-935E-7E4D85A1627C

Q36583022-FE5FF51C-0903-4A66-AC13-BF47740FF6FA

P2860

Q36583022-0F13B9C6-081A-4947-B0EF-5E633167EDB4

Q36583022-1B4D0E7E-FDE4-4CC1-A029-CB435E461EB9

Q36583022-2036C02F-7771-49DA-B9BA-7AAD8E4EFCDE

Q36583022-4639B12B-534A-4B7E-BE6E-37B4E5AF4C83

Q36583022-5C6C253D-2CE6-4180-B6E9-3FCA9D32F0C3

Q36583022-61A0C9C8-215A-4DD9-AB9D-ECAF6DD23DA7

Q36583022-6CF23956-9D70-41D6-966B-8FDD977FADD0

Q36583022-71C080C7-0F54-4682-9518-48DBB46B1AFE

Q36583022-8280F42A-6DD0-4731-AB75-7B83D04C842A

Q36583022-8F697929-FFCD-4ED5-BDD0-836D5866EF85

P304

Q36583022-7DF2B16F-C2D2-4DA9-B612-37743B6C7F8C

P31

Q36583022-4A050F9B-B362-4104-9B10-7DFB0EB7EBF5

P356

Q36583022-B265E383-884D-4AF8-893E-3B2A159C0439

P407

Q36583022-7D073218-EFD6-465E-BED1-8FC211345CA5

P433

Q36583022-73A0BB57-FA89-4B28-9BF1-EE7B23272A44

P478

Q36583022-05A871AE-8595-470A-8C8E-3066E730D4D0

P577

Q36583022-01CC27DA-15EA-4304-9D6D-2A7C26012DE2

P698

Q36583022-EB2927E3-45B1-422F-A279-3E08E96084C1

P932

Q36583022-6E5DE687-1871-4F94-9664-D02A7950DB71

P356

PNAS.1211850110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Changes in the local tumor mic ...... lure of vaccines after surgery

@en

P2093

Brendan Judy

http://www.w3.org/2001/XMLSchema#string

Edmund K Moon

http://www.w3.org/2001/XMLSchema#string

Evgeniy Eruslanov

http://www.w3.org/2001/XMLSchema#string

Guanjun Cheng

http://www.w3.org/2001/XMLSchema#string

Jarrod Predina

http://www.w3.org/2001/XMLSchema#string

Jing Sun

http://www.w3.org/2001/XMLSchema#string

Liang-Chuan Wang

http://www.w3.org/2001/XMLSchema#string

Steven Albelda

http://www.w3.org/2001/XMLSchema#string

Sunil Singhal

http://www.w3.org/2001/XMLSchema#string

Veena Kapoor

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Cancer statistics, 2010

Progress in human tumour immunology and immunotherapy.

Adjuvant immunotherapy for solid tumors: from promise to clinical application.

Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models.

Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery.

Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

P304

E415-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1211850110

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23271806

http://www.w3.org/2001/XMLSchema#string

P932

3562776

http://www.w3.org/2001/XMLSchema#string